Gilead second-quarter sales rise 8%, beating Wall Street estimates
Gilead Sciences reported Q2 product sales up 8% and revenue up 10% to $7.8B, beating LSEG estimates of $7.4B, driven by HIV drugs and cancer drug Trodelvy and liver drug Livdelzi. The company posted an adjusted loss of $6.75 per share. It raised the lower end of its 2026 revenue outlook and cut its expected adjusted loss range. Reuters.
How this was made
The 30-second read
Why it matters
The combination of a revenue beat, better-than-expected adjusted loss per share, and a narrowed 2026 adjusted loss range is likely to support estimates and sentiment, while product mix and acquisition charges add uncertainty to forward margin expectations.
Market read
Traders can update biotech positioning based on the reported Q2 beat and the narrowed 2026 adjusted loss range, with product-level detail highlighting where growth is accelerating.
What to watch
Veklury COVID sales fell 81%, and the adjusted loss per share still reflects a large quarterly net loss, so traders should watch whether guidance improvement is driven by one-off factors versus durable demand.
Background
Gilead’s Q2 results include strong HIV prevention and treatment growth, alongside quarterly losses attributed to acquisition-related costs and weaker cell therapy performance.
Ticker impact
Gilead reported Q2 product sales up 8% to $7.8B, beating $7.4B expectations, and raised the lower end of its 2026 revenue outlook.
Near-term upside bias versus consensus given the beat and modestly improved 2026 loss range, though earnings quality is mixed by acquisition charges and cell therapy decline.
The article provides multiple hard datapoints: revenue beat, adjusted loss per share better than expected, raised guidance range, and specific product growth rates. It also flags quarterly loss driven by acquisition costs, which can cap the magnitude of the reaction.
Market effects
Reinforces demand strength in HIV prevention and treatment franchises (PrEP expansion, Descovy/Biktarvy growth) within large-cap biotech.
Limited, primarily affects US biotech sentiment rather than a broad regional macro driver.
Moderate, as Gilead’s HIV and oncology/liver portfolio performance can influence global peer read-across for chronic therapies.
Counterpoint
The headline beat may be tempered by acquisition-related costs and a 14% drop in cell therapy sales, suggesting underlying mix and cost discipline remain key.
Key entities
- companyGilead Sciences
Reported Q2 revenue and product sales growth, beat consensus, and updated 2026 adjusted loss and sales outlook.
- personDaniel O’Day
Gilead CEO cited HIV sales growth and PrEP expansion as drivers of 2026 base business revenue expectations.
- companyArcellx
Cell therapy acquisition referenced as part of the acquisition-related charges impacting the quarter.
- companyOuro Medicines
Autoimmune drug acquisition referenced as part of the acquisition-related charges impacting the quarter.
- companyTubulis
Cancer drug acquisition referenced as part of the acquisition-related charges impacting the quarter.
